Burns Matteson Capital Management, LLC Gilead Sciences, Inc. Transaction History

Burns Matteson Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	SELL	$73.27 - $83.09 $564,545 - $640,208	-7,705 Closed	0 $0
Q3 2023 Jan 12, 2024	BUY	$73.94 - $80.67 $569,707 - $621,562	7,705 New	7,705 $577 Million
Q1 2023 Dec 11, 2023	SELL	$77.31 - $88.08 $699,191 - $796,595	-9,044 Closed	0 $0
Q4 2022 Dec 11, 2023	BUY	$62.32 - $89.47 $563,622 - $809,166	9,044 New	9,044 $776 Million
Q3 2022 Dec 11, 2023	SELL	$59.54 - $68.01 $748,775 - $855,293	-12,576 Closed	0 $0
Q2 2022 Dec 11, 2023	BUY	$57.72 - $65.01 $725,886 - $817,565	12,576 New	12,576 $777 Million
Q1 2022 Dec 11, 2023	SELL	$57.92 - $72.58 $504,656 - $632,389	-8,713 Closed	0 $0
Q4 2021 Dec 11, 2023	BUY	$64.88 - $73.64 $565,299 - $641,625	8,713 New	8,713 $632,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Burns Matteson Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Burns Matteson Capital Management, LLC with notifications on news.